摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(3-chloro-4-fluoro-phenoxy)-1-methyl-1H-indole-3-carbaldehyde | 1057257-10-9

中文名称
——
中文别名
——
英文名称
4-(3-chloro-4-fluoro-phenoxy)-1-methyl-1H-indole-3-carbaldehyde
英文别名
4-(3-Chloro-4-fluorophenoxy)-1-methylindole-3-carbaldehyde;4-(3-chloro-4-fluorophenoxy)-1-methylindole-3-carbaldehyde
4-(3-chloro-4-fluoro-phenoxy)-1-methyl-1H-indole-3-carbaldehyde化学式
CAS
1057257-10-9
化学式
C16H11ClFNO2
mdl
——
分子量
303.72
InChiKey
HPZLRNBQWKXSKB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    31.2
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    磷酰基乙酸三乙酯4-(3-chloro-4-fluoro-phenoxy)-1-methyl-1H-indole-3-carbaldehyde 在 sodium hydride 作用下, 以 四氢呋喃 为溶剂, 反应 16.17h, 生成 Ethyl 3-[4-(3-chloro-4-fluorophenoxy)-1-methylindol-3-yl]prop-2-enoate
    参考文献:
    名称:
    3-Acrylamide-4-aryloxyindoles: Synthesis, biological evaluation and metabolic stability of potent and selective EP3 receptor antagonists
    摘要:
    A series of potent and selective EP3 receptor antagonists are described. Utilizing a pharmacophore model developed for the EP3 receptor, a series of 3,4-disubstituted indoles were found to be efficient ligands for this target. These compounds showed high selectivity over IP, FP and other EP receptors. An optimized molecule 7c featured a sound pro. le and potency in the functional rat and human platelet aggregation assays. (C) 2009 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2008.12.112
  • 作为产物:
    参考文献:
    名称:
    3-Acrylamide-4-aryloxyindoles: Synthesis, biological evaluation and metabolic stability of potent and selective EP3 receptor antagonists
    摘要:
    A series of potent and selective EP3 receptor antagonists are described. Utilizing a pharmacophore model developed for the EP3 receptor, a series of 3,4-disubstituted indoles were found to be efficient ligands for this target. These compounds showed high selectivity over IP, FP and other EP receptors. An optimized molecule 7c featured a sound pro. le and potency in the functional rat and human platelet aggregation assays. (C) 2009 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2008.12.112
点击查看最新优质反应信息

文献信息

  • Sulfonamide peri-substituted bicyclics for occlusive artery disease
    申请人:Singh Jasbir
    公开号:US20060079520A1
    公开(公告)日:2006-04-13
    Acyl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula A representative example is:
    酰基磺酰胺,带有周取代的融合双环环化合物,用于治疗或预防前列腺素介导的疾病或症状。这些化合物的一般公式为 代表性示例是:
  • Carboxylic acid peri-substituted bicyclics for occlusive artery disease
    申请人:Singh Jasbir
    公开号:US20060142355A1
    公开(公告)日:2006-06-29
    Peri-substituted, fused bicyclic ring carboxylic acids useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula A representative example is:
    揭示了对于治疗或预防前列腺素介导的疾病或病状有用的取代周边,融合双环环酸类化合物。这些化合物的一般公式为。一个代表性的例子是:
  • SULFONAMIDE PERI-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE
    申请人:Singh Jasbir
    公开号:US20090291948A1
    公开(公告)日:2009-11-26
    Acyl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula A representative example is:
    本发明揭示了用于治疗或预防前列腺素介导的疾病或病状的酰基磺酰胺,周围取代,融合的双环环化合物。这些化合物的一般公式为。其中,代表性的例子为:
  • SULFONAMIDE PERT-SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE
    申请人:Decode Genetics
    公开号:EP1812388A1
    公开(公告)日:2007-08-01
  • CARBOXYLIC ACID PERI - SUBSTITUTED BICYCLICS FOR OCCLUSIVE ARTERY DISEASE
    申请人:Decode Genetics, Inc.
    公开号:EP1814881A2
    公开(公告)日:2007-08-08
查看更多